[go: up one dir, main page]

WO2025076450A1 - Peptide conjugates derived from natural toxin and machine learning, binding to the claudin-4 (cldn4) for the radionuclide imaging and therapy of pancreatic cancer - Google Patents

Peptide conjugates derived from natural toxin and machine learning, binding to the claudin-4 (cldn4) for the radionuclide imaging and therapy of pancreatic cancer Download PDF

Info

Publication number
WO2025076450A1
WO2025076450A1 PCT/US2024/050092 US2024050092W WO2025076450A1 WO 2025076450 A1 WO2025076450 A1 WO 2025076450A1 US 2024050092 W US2024050092 W US 2024050092W WO 2025076450 A1 WO2025076450 A1 WO 2025076450A1
Authority
WO
WIPO (PCT)
Prior art keywords
cldn4
claudin
therapy
pancreatic cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/050092
Other languages
French (fr)
Inventor
Katherine W Ferrara
Jai Woong Seo
James Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2025076450A1 publication Critical patent/WO2025076450A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Chemical compounds have been designed specifically from Claudin-4 binder peptides (C4BP) for radiopharmaceuticals. Specifically, compounds and compositions integrating C4BP have been designed with the distinct application in pancreatic cancer detection and therapy. Embodiments are compounds having a peptide, spacer (or without spacer), and chelator where this compound binds to CLDN4. The compound can incorporate the metallic radioisotopes to produce radiopharmaceuticals. Applications for these compounds include diagnostic procedures, therapeutic interventions, and targeted delivery of radionuclides to tissues that express CLDN4. Methods detailed herein delineate the use of radiopharmaceutical with CPB for diagnosis, treatment, and targeted delivery within CLDN4 expressing tissues.

Description

Figure imgf000003_0003
Figure imgf000003_0014
Figure imgf000003_0017
Figure imgf000003_0001
Figure imgf000003_0006
Figure imgf000003_0008
Figure imgf000003_0011
Figure imgf000003_0015
Figure imgf000003_0016
Figure imgf000003_0012
Figure imgf000003_0002
Figure imgf000003_0005
Figure imgf000003_0007
Figure imgf000003_0009
Figure imgf000003_0010
Figure imgf000003_0013
Figure imgf000003_0018
Figure imgf000003_0004
Figure imgf000003_0019
Figure imgf000003_0020
Figure imgf000003_0021
Figure imgf000003_0022
Figure imgf000003_0023
Figure imgf000003_0024
Figure imgf000003_0025
Figure imgf000003_0026
Figure imgf000003_0027
Figure imgf000003_0028
Figure imgf000003_0029
Figure imgf000003_0030
Figure imgf000003_0031
Figure imgf000003_0032
Figure imgf000003_0033
Figure imgf000003_0034
Figure imgf000003_0035
Figure imgf000003_0036
Figure imgf000003_0037
Figure imgf000003_0038
Figure imgf000003_0039
Figure imgf000003_0040
Figure imgf000003_0041
Figure imgf000003_0042
Figure imgf000003_0043
Figure imgf000003_0044
Figure imgf000003_0045
Figure imgf000003_0046
Figure imgf000003_0047
Figure imgf000003_0048
Figure imgf000003_0049
Figure imgf000003_0050
Figure imgf000003_0051
Figure imgf000003_0052
Figure imgf000003_0053
Figure imgf000003_0054
Figure imgf000003_0055
Figure imgf000003_0056
Figure imgf000003_0057
Figure imgf000003_0058
Figure imgf000003_0059
Figure imgf000003_0060
Figure imgf000003_0061
Figure imgf000003_0062
Figure imgf000003_0063
Figure imgf000003_0064
Figure imgf000003_0065
Figure imgf000003_0066
. ,
Figure imgf000003_0067
Figure imgf000003_0068
Figure imgf000003_0069
Figure imgf000003_0070
Figure imgf000003_0071
, - . . , , , , . , . . , , . - , . . , .
Figure imgf000004_0002
Figure imgf000004_0003
Figure imgf000004_0004
Figure imgf000004_0005
. -, - 2 - - 2 ,
Figure imgf000004_0001
-, -2- - - , -, -2- -- , - , - 2
Figure imgf000007_0001
, 4, 44,1,2 4 7 m 111, 1. ,,,,,, , - , ,,, , , 47,7.,,, 1, 14 , 11 177 1 1 212 21 22 22 22 227 , , , , -. . , .' , . ,
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000008_0004
Figure imgf000008_0005
.- ... ’ . . ... . . ., - .- -2- --2 4- .. , .- 4- 2- -2-2- - 2 4.-.-.2- -.2 -. .- - .. , , , - , . , . - - , . - . , . - .- . 4- -2-re -2. -.- 2-. ER -2 - .4- . . .. , . ,, ~ ,- , - ..4- -2- .2 , . , . .. . - LL-tTomatoLL- tTomato reE,R , . ..4- - n+ . .-,. ..,
Figure imgf000010_0001
Figure imgf000010_0002
- , . ..- . – - . . , -,. , , . - , . -, ., , , , . - ., , .. . . . 177-- . - .. , , , - . .- , .. , .. .’, , ,, ,. . . . , , ’ , . , , , . - D, . . - ....D. – , . , - .-. ’ , -2- . -2. 4 4 2.. - -2- - - , 4- -2- -2 ... .,. ... - ~ .. ~ . LSL-G12D/.+ LSL-tTom-ato/LSL-tTomato CreER / . , .-.4- -2- -2=, - ~. , .-. - .-. - ~ ~ .. ~ , . .. , , . . , - -,, , - - ., , .. -, = . ., , ., . , . . - - ..,, ., . . . . - ,. , . . , . , , , , .. , - Chelator—spacer—claudin-4 binding = - 2 , , - - , . , - -2, - . - , Chelator—spacer— cla cudin-4 binding X yclic peptide
Figure imgf000016_0001
. , - - , , .- - . , . , - - -2, -- . - , chelator l spacer H l R1 N claudin-4
Figure imgf000017_0001
. , - - , . - . .- - -2 -- . - . , , 4- 44 1 4 ,,,1,2,4,7,,,,m, -- ,, 47 7 1 14 , 11 177 1 1 212 21 22 , 22, 22, 227,,,,,7,,, 177, 21,2,, 22,., . - . - - , - . =,,,,,,,, ,, H N O n On =,,,,,,,,,, N O H n O ,,,,,,,,, H N n O - . HO O O N N N ,,- O HO O OH N O N HO N ,,,,,,-- - O N O HO O OH N O HO N N OH O N --- -,,,- HO O -,,,- O OH N O HO N N O N ,,,,,,-- - HO O O OH N O HO N N OH O N --- -,,,- HO O -,,,-- N O HO N N O N ,-- -,,,- NH H2N NH HN HN NH NH HN -,,-,- ..- ,,-- ..- -,- - O H2N NH - - HN O O O O HN HO N HO N ---- O N HN - OH - - -'--'-- HO O O OH N N N O O O -,,”,”-- O -’-- H OH HO O O OH N N N ---- - O O O OH --- OH OH HO O O OH N N N - O O O OH OH OH --,-----,- ---,- N O O N N OH O HN N ,','','''--- -. HO HN O O N HN O OH HO ,- N O O N ,- - -- . ---,- --- .. .. - – - - - - -2 . . , , - . . . . , .., , - . -2- −. . . ., ... +,-1221 -- -2- -.- +. ., ... , 12412 - -2- - -- -- . - -.. -2- . −- . ., ... +, 1421 2 -- -2- -. ., .. -. +,.41212 - -2- - - -- . -. - . -2- . −- . ., ... +, 12 2 - -- - . . - -. . +,122 ., .. -, -2 . - . - - ... +,741112 ., -, -2 . - ., . . ,- . + 121227 - -, - 4- -2- 4 2 - . . - . +,1-247 ., ..- --, -- -2 . . ... ,- -. + 1127 ., 4 1/2=.,4 2 ,. . -2- . ,. , .,.. , - , ° - . . . . . ~.-. . , . - . , , , ,, - ., - , , = - , ~ . - 4- ,.. . . , =,= , 4 4 - - ~- .. , , . . . - .. , , . . .... – -

Claims

. , , -, -2- -2
Figure imgf000027_0001
-, -2- - - , -, -2- -- - , -2
Figure imgf000030_0001
. , , , , ,, , 4 m, 111, 1. , 44,1 2 4 7 , -. , , , ,, , ,,, 47 1 14 , 11177 1 1 212 21 22, 22, 22,7 2,27., . -. , -
PCT/US2024/050092 2023-10-05 2024-10-04 Peptide conjugates derived from natural toxin and machine learning, binding to the claudin-4 (cldn4) for the radionuclide imaging and therapy of pancreatic cancer Pending WO2025076450A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363542580P 2023-10-05 2023-10-05
US63/542,580 2023-10-05

Publications (1)

Publication Number Publication Date
WO2025076450A1 true WO2025076450A1 (en) 2025-04-10

Family

ID=95283990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/050092 Pending WO2025076450A1 (en) 2023-10-05 2024-10-04 Peptide conjugates derived from natural toxin and machine learning, binding to the claudin-4 (cldn4) for the radionuclide imaging and therapy of pancreatic cancer

Country Status (1)

Country Link
WO (1) WO2025076450A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280687A1 (en) * 2005-03-18 2006-12-14 Zhen Cheng Compounds for tissue imaging and methods of use thereof
US20090252677A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for In Vivo Targeting of Active Cysteine Proteases
US20110104263A1 (en) * 2008-04-30 2011-05-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
US20120220870A1 (en) * 2011-02-28 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Optical imaging probes, optical imaging systems, methods of optical imaging, and methods of using optical imaging probes
WO2022076523A1 (en) * 2020-10-06 2022-04-14 Washington University Methods and compositions for imaging and treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280687A1 (en) * 2005-03-18 2006-12-14 Zhen Cheng Compounds for tissue imaging and methods of use thereof
US20090252677A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for In Vivo Targeting of Active Cysteine Proteases
US20110104263A1 (en) * 2008-04-30 2011-05-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
US20120220870A1 (en) * 2011-02-28 2012-08-30 The Board Of Trustees Of The Leland Stanford Junior University Optical imaging probes, optical imaging systems, methods of optical imaging, and methods of using optical imaging probes
WO2022076523A1 (en) * 2020-10-06 2022-04-14 Washington University Methods and compositions for imaging and treating cancer

Similar Documents

Publication Publication Date Title
Kiess et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
Kalidindi et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals
US10842893B2 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
Ogawa et al. Evaluation of Ga-DOTA-(D-Asp) n as bone imaging agents: D-aspartic acid peptides as carriers to bone
WO2025076450A1 (en) Peptide conjugates derived from natural toxin and machine learning, binding to the claudin-4 (cldn4) for the radionuclide imaging and therapy of pancreatic cancer
JP2016528299A5 (en)
WO2023165987A1 (en) Precursor markers and radiotracers with three or more targeting vectors for theranostics used in nuclear medicine
Wieder et al. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters
Bahrami-Samani et al. Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications
CN104321084A (en) Kit and method for producing a radiopharmaceutical
DE102008045937B4 (en) Radiopharmaceutical of a metal ion and a label precursor and use of the radiopharmaceutical
Dormehl et al. Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model
CA2420645A1 (en) Metal complexes for use in medical and therapeutic applications
ES2916550T3 (en) Meta-iodobenzylguanidine preparations and their precursors
ES2248522T3 (en) AMINODERIVADOS DE BIOTINA AND ITS CONJUGATES WITH COMPLAINTS AGENTS.
CA1300608C (en) 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
US6844425B1 (en) Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
WO2000050086A1 (en) Molecules for the treatment and diagnosis of tumors
Kim et al. Early diagnosis of Burkitt lymphoma on the mandible: a case report
ES2320805T3 (en) RADIOMARCATED NANOPARTICLES.
US6245316B1 (en) Enhancement of delivery of radioimaging and radioprotective agents
US8709380B1 (en) Targeting agents for enhancing radiation therapy
Grus PSMA inhibitor-based radiopharmaceuticals for diagnosis and therapy of prostate cancer
EP3747874B1 (en) Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24875533

Country of ref document: EP

Kind code of ref document: A1